Company · Private
Metro International Biotech
Developing pharmaceutical-grade NAD+ precursors intended to be tested as drugs rather than supplements.
EvidenceModerate
Listing
Private
Ticker
—
Headquarters
Worcester, US
Founded
2016
Technology
NAD+ precursors
Category
Market cap
Private
Longevity thesis
NAD+ biology only becomes investable when it is held to a clinical evidence standard.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| MIB-626 | Phase 2 | Cardiometabolic and muscle function |
Recent developments
- 27 May 2026Completed enrolment in a cardiometabolic Phase 2.
Scientific evidence
EvidenceModerate
Human trials underway; consumer NAD+ evidence remains weak and should not be conflated.
LONGEFI analysis
The distinction between clinical NAD+ programmes and the supplement market is the single most misunderstood point in this category.
Analysis is research commentary. It is not investment advice or a recommendation.